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Three calmoduIin (CM) antagonists W-7, W-5 and tri~uoperazine (TFP) were tested for ability to prevent 
aggregation of human, guinea pig, and rabbit platelets induced by 7.88 PM PAF. The naphthalene sulfon- 
amide derivatives, W-7 and W-S, were active in al1 species, W-S being 1,5-5.7-times less potent than W-7, 
in accordance with W-5 being a weaker CM inhibitor. E&-Values for TFP were 155, 160 and 255 ,uM 
for rabbit, human and guinea pig platelets, respectively. Results are consistent with the notion that some 
substances antagonizing CM may inhibit PAF aggregation effects. W-7 is most effective on human 
platelets (ED50 51.5 PM). High concentrations of TFP required to antagonize PAF-induced aggregation 
cautions against ascribing its effects solely to an inhibitory effect on CM. 
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1. INTRODUCTlON 
Platelet activating factor (PAF) (I-cu-lecithin, ,& 
acetyl, y-0-alkyl) is a potent aggregator of 
platelets from certain species, including human, 
guinea pig and rabbit [l]. The precise mechanism 
of action of PAF in producing this effect is 
unknown. There is evidence that calcium is a key 
mediator of PAF action since caIcium channel 
blockers may inhibit PAF-induced aggregation 
[1,2]. In addition, the calmodulin (CM) antago- 
nists W-7 [~-(6-aminohexyl)-5-chloro-l-naphtha- 
lenesulfonamide] [3] and trifluoperazine (TFP) [4] 
may also inhibit the aggregating effect of PAF 
[5,6]. To further test the specificity of the CM an- 
tagonist actions against PAF, we performed ex- 
periments comparing W-7, its non-chloro-less po- 
tent analog, W-5 [3] and TFP on PAF-induced ag- 
gregation in human, guinea pig and rabbit 
platelets. 
2. MATERIALS AND METHODS 
2.1. Pffftelet preparation 
New Zealand rabbits and Hartley strain guinea 
pigs of either sex were obtained from local com- 
mercial sources. The animals were anesthetized 
with an intraperitoneal injection of pentobarbital 
sodium. Whole blood was obtained by cardiac 
puncture using a 19 gauge butterfly needle 
(Abbott), which drained into a Falcon plastic tube 
containing 3.8% sodium citrate as an anticoagu- 
lant (1: 9 parts blood). The blood was centrifuged 
in a IEC Centrifuge at 200 x g for 10 min at room 
temperature. Platelet rich plasma (PRP) was then 
removed, and placed into aggregometer tubes. The 
PRP was equilibrated at room temperature for 
30 min prior to any aggregation studies [7]. 
Blood was obtained from normal male 
volunteers (24-54 years). A 19 gauge butterfly 
needle was placed into an antecubital vein, and 
blood allowed to flow into a plastic tube contain- 
ing 3.8% sodium citrate (1:9 parts biood). PRP 
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then was prepared and processed as described for 
the animal preparations. 
2 -2. Ratelet aggregation 
Platelet aggregation was studied with ChronoIog 
dual channel aggregometers and recorders as in 
[5]. PRP (0.45 ml) was placed into aggregometer 
tubes containing a magnetic stirring bar. The PRP 
sample was placed into the aggregometer and equi- 
librated for 1 min before addition of inhibitors or 
aggregating substances. All studies were done at 
37.5”C. Experiments were completed within 2 h of 
the preparation of the PRP sample. 
2.3, Llfugs and chemicals 
Platelet activating factor (PAF) (La-lecithin, & 
acetyl, y-O-alkyl) was obtained from Calbiochem 
(La Jolla CA). The material was dissolved in 60% 
ethanol. In the volumes used (l-5pVO.45 ml 
PRP), the solvent did not promote detectable ag- 
gregation of the PRP. 
The calmodulin antagonists W-7 [N-(B-amino- 
hexyl)-5-chloro-1-naphthalene-sulfonamide] and 
W-5 [N-(6-aminohexyl)-l-naphtalenesulfonamide 
-HCI] were purchased from Rikaken Co. (Nagoya). 
W-7 compound is a potent and specific calmodulin 
antagonist [3]. W-7 and W-5 were dissolved in 
distilled water and kept at 4°C. Dilutions of the 
stock solution were made fresh daiIy. Exposure of 
the PRP to the W-7 solvent (I-lO pi) neither pro- 
duced detectable aggregation, nor did it alter the 
normal aggregation response to PAF. PRP sam- 
ples were treated with the antagonists for 5 min at 
37°C in the aggregometer before addition of PAF. 
The effect of the antagonists on PAF-induced ag- 
gregation was expressed as percent inhibition of 
the control response to PAF obtained in the 
absence of the inhibitor.’ 
Triffuoperazine (TFP) also was used as a CM 
antagonist [4]. It was obtained from Smith, Kline 
and French Labs (Philadelphia PA). 
2.4 Determination of EDJO 
Log dose-percent inhibition curves for the 3 CM 
antagonists were determined using 7.88 PM 
(4.4,~g/ml) PAF as the aggregating substance. 
Three to five doses for each antagonist were tested 
vs PAF, and the mean dose-response curve plot- 
ted. From these curves, the _!ZDSO for each an- 
tagonist was estimated by graphic extrapolation. 
3. RESULTS 
Fig. 1 depicts a typical dose-response curve for 
the inhibitory effect of W-5 on PAF-induced ag- 
gregation of guinea pig pIateIets (PRP). From such 
experiments, the EDso-vaiues for W-5, W-7 and 
TFP were determined for platelets from humans, 
guinea pigs and rabbits, as in section 2. Table 1 
compares the EDso-values for the inhibitory effect 
of the CM antagonists on PAF-induced platelet ag- 
gregation. Our previous finding [5] with W-7 in- 
dicates that it is most effective against PAF in 
human platelets (ED50 = 51.5 FM). W-5, which is 
an analog of W-7 devoid of the chloro substitu- 
tion, and is 6-7-times weaker as an inhibitor of 
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Fig. 1, Dose-response curve for the CM antagonist W-5 
vs PAF-induced aggregation of guinea pig platelets 
(PRP). Effect of W-S is expressed as To inhibition of the 
normal PRP aggregation response to a challenge dose 
(7.88pM) of PAF. The ED_W is estimated graphically. 
Each point is the mean *SEM of 3-5 expt. 
Table I 
rnhibition by calmodulin antagonists of platelet 
aggregation produced by platelet activating factor (PAF) 
EDTO OcW 
Species w-7 w-5 TFP 
Human 51sb 295 160 
Guinea Pig 365 710 25.5 
Rabbit 310 470 1.55 
a Amount of drug needed to produce a 50% decrease 
(5 min pretreatment) in maximum aggregation of 
platelets induced by PAF (7.88 PM) 
b From IS] 
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CM [3], was almost 6-times less potent an inhibitor 
of PAf on human platelets compared to W-7. 
Guinea pig platelets, which are very responsive to 
the aggregating effect of PAF[l] were com- 
paratively resistant o the action of W-7, W-5 and 
TFP. Similarly, TFP a reported antagonist of PAF 
[6], was effective only with EDSO > 1OOpM 
(155-255 PM). This suggests TFP may not be act- 
ing solely as a CM inhibitor, since > 100 FM is 
thought to represent a non-CM effect of this drug 
(non-stereo-specific hydrophobic interactions) [8]. 
In summary, PAF-induced platelet aggregation 
from 3 responsive species may be antagonized by 
3 putative CM antagonists. W-7 is the most potent 
against PAF-induced aggregation of human plate- 
lets. W-5, an analog of W-7 with weaker CM inter- 
action properties, showed predictably less effects 
on all 3 species. The actions of TFP must be 
cautiously interpreted, in view of the fact that this 
agent may have actions independent of CM in- 
teraction in the concentrations needed to inhibit 
PAF-induced aggregation. 
4. DISCUSSION ACKNOWLEDGEMENTS 
The ability of the 3 CM antagonists to inhibit 
PAF-induced aggregation may be interpreted to 
support the concept that part of PAF’s effect is 
mediated through CM-dependent processes. The 
specificity and potency of W-7 as a CM antagonist 
[3] is reflected in its action on human platelets. 
This is not shown in guinea pig and rabbit 
platelets, however. W-7 at > 100,uM are thought 
to have effects independent of CM interaction [3]. 
Similarly the fact that the E&-values for TFP are 
> 150 PM suggests that this inhibitor also may 
have non-CM effects, as detailed in [8]. 
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